Regulatory
FDA Requires a Class-Wide GLP-1 Label Warning for a Rare Eye Condition, NAION
On November 9, 2026, the FDA ordered every GLP-1 receptor agonist maker to add a potential NAION (a rare optic-nerve condition that can cause sudden vision loss) warning to the Warnings and Precautions section. The change covers semaglutide, tirzepatide, orforglipron and the rest of the class, however they are prescribed, including by telehealth.
Quick answer
On November 9, 2026, the FDA issued a Drug Safety Communication requiring all GLP-1 receptor agonist makers to add information about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, painless vision loss in one eye) to the Warnings and Precautions section of their labeling. The requirement applies to the whole class, including Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, and to GLP-1 drugs prescribed through telehealth. The FDA described a potential risk and did not conclude that the drugs cause NAION.
Key takeaways
- →The FDA is requiring every GLP-1 receptor agonist application holder to add a potential NAION risk to the Warnings and Precautions section of the drug label, a formal labeling action rather than a proposal.
- →The warning spans the full class: exenatide, liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide combinations, semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo).
- →In the FDA's meta-analysis of 126 randomized trials (134,253 patients), there were 15 probable NAION events: 10 on a GLP-1 drug and 5 on placebo, an incidence of 6.4 versus 3.8 per 100,000 person-years.
- →The FDA said the signal reflects a potential increased risk of a rare event and that a review of animal data did not identify a mechanism, so the agency did not conclude the drugs cause NAION.
- →GLP-1 drugs are the core of telehealth weight-loss and metabolic prescribing, so the update means telehealth clinicians now counsel patients to report sudden vision changes and seek prompt eye care.
The FDA has told every maker of a GLP-1 receptor agonist to warn about a rare eye condition. In a Drug Safety Communication dated November 9, 2026, the agency required that information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) be added to the Warnings and Precautions section of the labeling for the entire class. The action reaches the best-known names in weight management and diabetes, semaglutide and tirzepatide among them, and it applies no matter how the prescription is written, including through the telehealth platforms that now drive much of GLP-1 demand.
What the FDA did
The FDA issued a Drug Safety Communication requiring all GLP-1 receptor agonist application holders to add a potential increased risk of NAION to the Warnings and Precautions section of their product labeling. This is a required labeling change, not a proposed rule and not a restriction on the drugs' approved uses. The agency framed it as formalizing a safety signal it had been tracking, with low absolute event rates, rather than a finding that the medications cause the condition.
For prescribers, the communication asks clinicians to make patients aware of the risk, to tell them to report any sudden, painless decrease in vision, visual field loss or other visual disturbance right away, and to refer suspected cases promptly to an ophthalmologist. It adds that clinicians may consider stopping the drug in a patient who develops NAION unless the benefits of treatment clearly outweigh the risk. For patients, the FDA lists symptoms to watch for, including sudden vision loss, blind spots, color distortion and blurry central vision.
Which drugs are affected
The requirement is class-wide. The products named by the FDA include:
- Exenatide (marketed as generics; the Byetta new drug application was voluntarily withdrawn for reasons unrelated to safety or effectiveness).
- Liraglutide (Victoza, Saxenda) and the liraglutide plus insulin degludec combination (Xultophy).
- Dulaglutide (Trulicity).
- Lixisenatide plus insulin glargine (Soliqua).
- Semaglutide (Ozempic, Rybelsus, Wegovy).
- Tirzepatide, a dual GIP and GLP-1 agonist (Mounjaro, Zepbound).
- Orforglipron, an oral GLP-1 drug (Foundayo).
What NAION is
NAION is non-arteritic anterior ischemic optic neuropathy. The FDA describes it as a rare condition that can cause acute, painless, decreased vision in one eye and can result in permanent vision loss. It is linked to reduced blood flow to the front of the optic nerve. Once NAION occurs in one eye, the other eye carries an increased risk. Known risk factors overlap heavily with the conditions GLP-1 drugs are prescribed to treat, and include diabetes, high blood pressure, sleep apnea, smoking, anemia and kidney disease.
The evidence behind the warning
The FDA said it weighed several data streams. Its meta-analysis pooled 126 randomized controlled trials covering 134,253 patients and 288,879 person-years. It counted 15 probable NAION events: 10 in patients on a GLP-1 drug, 5 on placebo and none on other glucose-lowering medicines. That worked out to 6.4 events per 100,000 person-years with GLP-1 drugs against 3.8 with comparators.
The review traces back to a July 2024 study in JAMA Ophthalmology, a retrospective cohort of patients seen by neuro-ophthalmologists at a single academic center, which reported a higher NAION risk with semaglutide. Among patients with type 2 diabetes the hazard ratio was 4.28 (95% confidence interval 1.62 to 11.29), and among patients who were overweight or obese it was 7.64 (2.21 to 26.36). The FDA noted the study's limitations but judged that further assessment was warranted. A separate FDA Sentinel real-world study of adults with type 2 diabetes starting a GLP-1 drug, an SGLT-2 inhibitor or a DPP-4 inhibitor from 2019 to 2024 found NAION incidence in a similar band across the three groups (roughly 26 to 32 per 100,000 person-years). In that study the risk versus DPP-4 inhibitors was statistically significant (hazard ratio 1.43, 1.02 to 2.01) while the comparison with SGLT-2 inhibitors was not (1.19, 0.91 to 1.54). A review of animal data did not identify a mechanism by which GLP-1 drugs would raise NAION risk.
How big is the risk
In absolute terms the numbers are small. General-population NAION incidence in adults over 50 runs about 2.3 to 10.2 cases per 100,000 people per year, and the event counts in the trial pool were in the low double digits across more than 134,000 patients. The FDA characterized the finding as a potential increased risk of a rare event and, because the risk factors for NAION track closely with diabetes and obesity, adverse-event data are hard to attribute cleanly to the drugs. The European Medicines Agency reached a narrower conclusion earlier, limiting its NAION review to semaglutide, while the US labeling change covers the entire class.
What this means for telehealth GLP-1 prescribing
GLP-1 drugs are the engine of telehealth weight management and metabolic care, prescribed at scale by direct-to-consumer platforms and virtual clinics. A Warnings and Precautions update applies to every prescription of these products, including those written in a video visit or an asynchronous online consult. In practice that means a telehealth clinician's intake and follow-up should surface NAION as a counseling point: patients should know to report any sudden, painless change in vision and to seek in-person eye care quickly rather than wait for a routine virtual check-in. The update does not change who may prescribe GLP-1 drugs or for what, and it does not pull any product from the market.
What patients and clinicians can do now
This is general information, not medical advice. A few reasonable steps while the labeling takes effect:
- If you take a GLP-1 drug and notice sudden, painless vision loss, a blind spot, color distortion or blurry central vision in one eye, seek prompt in-person eye care and tell the clinician you take a GLP-1 medication.
- Do not stop a prescribed medication on your own. Discuss any vision symptoms, and whether to continue, with the clinician who prescribed it.
- Ask a telehealth provider how they handle urgent symptoms that need an in-person exam, since NAION is diagnosed by an eye specialist, not over video.
- Read the updated Warnings and Precautions section and the FDA's Drug Safety Communication for the agency's own description of the risk.
Frequently asked questions
What did the FDA require on November 9, 2026?+
The FDA issued a Drug Safety Communication requiring every GLP-1 receptor agonist maker to add a potential increased risk of NAION to the Warnings and Precautions section of the drug label. It is a required labeling change that applies across the class.
Which GLP-1 drugs are covered?+
The full class, including exenatide, liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide combinations (Soliqua), semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo).
What is NAION?+
NAION, non-arteritic anterior ischemic optic neuropathy, is a rare condition tied to reduced blood flow at the front of the optic nerve. It can cause sudden, painless decreased vision in one eye and may lead to permanent vision loss. If it affects one eye, the other eye carries an increased risk.
Did the FDA say GLP-1 drugs cause NAION?+
No. The FDA described a potential increased risk based on its review, said the absolute event rates are low, and noted that a review of animal data did not identify a mechanism. The agency did not conclude that the drugs cause NAION.
How large is the risk in the FDA's data?+
In a meta-analysis of 126 trials covering 134,253 patients there were 15 probable NAION events (10 on a GLP-1 drug, 5 on placebo), an incidence of 6.4 versus 3.8 per 100,000 person-years. For context, background NAION incidence in adults over 50 is about 2.3 to 10.2 per 100,000 per year.
Does this affect GLP-1 drugs prescribed through telehealth?+
Yes. The labeling change applies to the products themselves, so it covers GLP-1 prescriptions written through telehealth as well as in person. It does not restrict who may prescribe or remove any product from the market. Patients should report sudden vision changes and seek prompt in-person eye care.
Should I stop my GLP-1 medication?+
This article is general information, not medical advice. Do not stop a prescribed medication on your own. If you notice vision symptoms, seek prompt eye care and discuss whether to continue with your prescribing clinician.
Sources
- 1.MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of a Rare but Serious Eye Condition · U.S. Food & Drug Administration
- 2.FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk · Pharmacy Times
- 3.FDA requires NAION warning across the GLP-1 receptor agonist class · Ophthalmology Times